4-fluoro-1-naphthylsulphonic acid | 316-70-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-fluoro-1-naphthylsulphonic acid
• 英文别名: 4-fluoro-naphthalene-1-sulfonic acid；4-Fluor-naphthalin-1-sulfonsaeure；4-Fluoronaphthalene-1-sulfonic acid
• CAS: 316-70-1
• 化学式: C₁₀H₇FO₃S
• 分子量: 226.228
• InChiKey: CLWXEHOCNHENJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氟萘-1-磺酰氯 在 水 作用下， 以 丙酮 为溶剂， 生成 4-fluoro-1-naphthylsulphonic acid
  参考文献：
  名称：

  Perumal, S.; Selvaraj, S.; Viswanathan, T. K., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1986, vol. 25, # 5, p. 436 - 438

  摘要：

  DOI：

文献信息

• New compounds
  申请人：——

  公开号：US20030158202A1

  公开（公告）日：2003-08-21

  The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system. 1

  本发明涉及一般式（I）的取代磺胺基化合物，其中P是磺胺基或酰胺基取代的磺酸，这些化合物可能有助于预防和治疗与肥胖、2型糖尿病和/或中枢神经系统紊乱有关的医疗状况。
• 5-HT7 receptor antagonists
  申请人：Torrens Jover Antoni

  公开号：US20060040978A1

  公开（公告）日：2006-02-23

  The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

  这项发明涉及具有对5-HT7受体具有药理活性的化合物，更特别地涉及一些四氢异喹啉取代磺胺基化合物，以及制备这些化合物的过程，包括含有它们的药物组合物，并且用于治疗和/或预防涉及5-HT的疾病，如中枢神经系统紊乱。
• Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
  申请人：Bloomfield Jonathon Nic

  公开号：US20050267152A1

  公开（公告）日：2005-12-01

  The present invention relates to glycine transporter inhibiting compounds of formula (I): for treating disorders mediated by GlyT1, wherein R 1 —R 9 are as in the description.

  本发明涉及公式（I）的甘氨酸转运抑制化合物，用于治疗由GlyT1介导的疾病，其中R1-R9如描述。
• 5-Ht7 Receptor Antagonists
  申请人：Torrens Jover Antoni

  公开号：US20090036480A1

  公开（公告）日：2009-02-05

  The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

  该发明涉及具有对5-HT7受体具有药理活性的化合物，更具体地涉及一些2,2a,4,5-四氢-1H-3-氮杂蒽基取代磺酰胺化合物，制备这些化合物的过程，包含它们的制药组合物以及它们用于治疗和/或预防5-HT参与的疾病，如中枢神经系统疾病的用途。
• 5-HT7 RECEPTOR ANTAGONISTS
  申请人：Jover Antoni Torrens

  公开号：US20090264458A1

  公开（公告）日：2009-10-22

  The invention relates to compounds having pharmacological activity towards the 5-receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

  本发明涉及具有对5-HT受体具有药理活性的化合物，更具体地涉及一些2,2a,4,5-四氢-1H-3-氮杂蒽取代磺酰胺化合物，制备这些化合物的方法，包含它们的制药组合物，以及它们用于治疗和/或预防5-HT参与的疾病，如中枢神经系统疾病的用途。